Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZIOverviewHYMPAVZI in ActionEfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& AdminDosingPen OverviewInjection OverviewPatient StoriesPatient
StoriesMeet a Real PatientIdentifying Potential PatientsResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site
Patients who may benefit from HYMPAVZI

Patients With Hemophilia A Without Inhibitors

Patients With Hemophilia B Without Inhibitors

Tab Number 3

Tab Number 4

Tab Number 5

Do you have patients like these in your practice?

 Age: 17Gaining independence, wants 1 less “variable” 
  • Currently on a subcutaneous prophylaxis treatment
  • Desires to maintain bleed protection
  • Interested in a fixed-dose,* prefilled pen option with straightforward administration and minimal prep
Lifestyle Considerations
  • Participates in sports
  • Wants to be self-sufficient, including with treatment†
  • Caregiver is interested in a non-factor treatment option
Why HYMPAVZI?
  • The HYMPAVZI pen is designed for ease of use. HYMPAVZI is available in a fixed-dose,* prefilled pen which means consistent dosing with no mixing, measuring, or lengthy prep for your patients1
  • HYMPAVZI uses an innovative mechanism, targeting TFPI to help achieve hemostasis, offering your patients an alternative treatment approach1-4
 Age: 60Wants to focus on personal pursuits 
  • Has been on routine factor-based prophylaxis treatment 
  • Starting to struggle with venous access 
  • Concerned about safety when it comes to treatment
  • Interested in non-factor treatment options 
Lifestyle Considerations
  • Wants to travel more
  • Values his hobbies and playing with his grandkids
Why HYMPAVZI?
  • The HYMPAVZI pen is designed for ease of use. HYMPAVZI is available in a fixed-dose,* prefilled pen, which means consistent dosing with no mixing, measuring, or lengthy prep for your patients1
  • HYMPAVZI uses an innovative mechanism, targeting TFPI to help achieve hemostasis, offering your patients an alternative treatment approach1-4
The recommended dosage of HYMPAVZI on day 1 is a loading dose of 300 mg (two 150 mg pens) by subcutaneous injection. On day 8 and thereafter, the weekly maintenance dose is 150 mg (one pen) by subcutaneous injection. A dose adjustment to 300 mg subcutaneous injection weekly can be considered in patients weighing ≥50 kg when control of bleeding events is judged to be inadequate by the healthcare provider. Safety and efficacy of HYMPAVZI at doses above 300 mg weekly have not been established.1 HYMPAVZI is intended for use under the guidance of a healthcare provider. After proper training in subcutaneous injection technique, a patient may self-inject or the patient’s caregiver may administer HYMPAVZI, if a healthcare provider determines that it is appropriate.1 Resources and support

Download educational resources that can support you and your patients

 See the resources LoadingMeet Peter, a real HYMPAVZI patient

Hear Peter's experience using once-weekly HYMPAVZI1

See Peter's story LoadingReferences:1. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2025. 2. Srivastava A, et al. Haemophilia. 2020;26(suppl 6):1-158. 3. Butterfield JSS, et al. Mol Ther. 2020;28(3):997-1015. 4. Pittman DD, et al. Res Pract Thromb Haemost. 2022;6(2):e12679.

Do you have patients like these in your practice?

 Age: 12Ready for a change
  • On routine prophylaxis and administers every 2 weeks. He does not time his infusions based on activities and has occasional breakthrough bleeds

  • Growing impatient with preparing and sitting through IV infusions

Lifestyle Considerations
  • Participates in sports with his peers
  • Prefers to not see needle due to needle fear

Why HYMPAVZI?
  • HYMPAVZI is a once-weekly, subcutaneous prophylactic treatment for hemophilia A or B without inhibitors that comes in a fixed-dose,* prefilled pen with a hidden needle1-3
 Age: 30Focusing on the next chapter in life
  • On routine factor-based prophylaxis treatment; administers every 10 days
  • Frustrated with IV infusions
  • Growing family
Lifestyle Considerations
  • Busy with his work and family, finding time to infuse is hard. He wants to spend less time thinking about when to infuse and preparing for administration
  • Interested in a prophylaxis treatment with straightforward administration
Why HYMPAVZI?
  • HYMPAVZI is a once-weekly, subcutaneous prophylactic treatment for hemophilia A or B without inhibitors that comes in a fixed-dose,* prefilled pen with a hidden needle1-3
The recommended dosage of HYMPAVZI on day 1 is a loading dose of 300 mg (two 150 mg pens) by subcutaneous injection. On day 8 and thereafter, the weekly maintenance dose is 150 mg (one pen) by subcutaneous injection. A dose adjustment to 300 mg subcutaneous injection weekly can be considered in patients weighing ≥50 kg when control of bleeding events is judged to be inadequate by the healthcare provider. Safety and efficacy of HYMPAVZI at doses above 300 mg weekly have not been established.1  Resources and support

Download educational resources that can support you and your patients

 See the resources LoadingMeet Peter, a real HYMPAVZI patient

Hear Peter's experience using once-weekly HYMPAVZI1

 Hear Peter’s story LoadingReferences:1. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2025. 2. Srivastava A, et al. Haemophilia. 2020;26(suppl 6):1-158. 3. Butterfield JSS, et al. Mol Ther. 2020;28(3):997-1015.
Patient Stories Resources and support

Download educational resources that can support you and your patients

 See the resources Loading

HYMPAVZI is a registered trademark of Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-HYM-USA-0601
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationVenous thrombotic events were reported in clinical studies with HYMPAVZI. Patients with independent risk factors for thromboembolic events may be at increased risk of thromboembolic events with use of HYMPAVZI. Consider the benefit and risk of using HYMPAVZI in patients with known risk factors for thromboembolism. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. A serious adverse reaction of venous thrombosis occurred in 0.9% of patients (1/116) in the open-label extension study. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).IndicationsHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.